Also known as: Almirall
Almirall is a Spanish pharmaceutical company focused on medical dermatology. Founded in 1944 and headquartered in Barcelona, it develops and commercializes products for skin-related conditions and other therapeutic areas. The company is publicly traded in Madrid under ticker ALM.
Two phase 3 trials demonstrate significant improvements in skin clearance and disease severity for children and adolescents with moderate-to-severe atopic dermatitis treated with targeted biologics.
The alopecia areata treatment market is projected to grow significantly through 2036, driven by rising prevalence and the anticipated launch of emerging therapies including JAK inhibitors and novel drug classes targeting immune pathways.
